Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,102.44 -712.12 (-1.83%) Hang Seng
17,936.12 -5.66 (-0.03%) FTSE 100
8,152.53 +5.67 (+0.07%) Bitcoin USD
66,139.82 -85.97 (-0.13%) CMC Crypto 200
1,382.82 -5.34 (-0.38%)
Fate Therapeutics, Inc. (FATE)
After hours:
| Previous close | 3.7600 |
| Open | 3.7000 |
| Bid | 3.6000 x 500 |
| Ask | 3.6300 x 1000 |
| Day's range | 3.5800 - 3.7700 |
| 52-week range | 1.6300 - 8.8300 |
| Volume | |
| Avg. volume | 2,386,373 |
| Market cap | 410.934M |
| Beta (5Y monthly) | 1.90 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.9200 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.64 |
GlobeNewswireFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 04, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that on June 1, 2024 the Company granted (i) a non-qualified stock option to one newly-hired employee to purchase a total of 65,000 shares of the Company’s common stock at an exercise p
- GlobeNewswire
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will present at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 3:00 PM ET in New York, New York. A l
Insider MonkeyFate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript
Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2024 Earnings Call Transcript May 11, 2024 Fate Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Fate Therapeutics First Quarter 2024 Financial Results Conference Call [Operator Instructions]. This call is […]
